| Date | Form | Description | Docs | XBRL | Pages |
| 12/08/16 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
|
85 |
| 12/07/16 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
138 | |
| 12/23/15 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
97 |
| 01/29/15 | 10-K/A | Annual report pursuant to Section 13 and 15(d) |
|
15 | |
| 01/29/15 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
101 |
| 04/16/14 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
41 | |
| 01/17/14 | 10-K/A | Annual report pursuant to section 13 and 15(d) |
|
|
6 |
| 01/16/14 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
111 | |
| 08/27/13 | ARS | Annual report to security holders |
|
108 | |
| 01/29/13 | 10-K | Annual report pursuant to section 13 and 15(d) |
|
|
244 |
Latest News & Events
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
Read More...Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
Read More...Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Read More...